RESEARCH MONOGRAPH · KDC-MN-117

MitoQ

May 9, 2026 Kodiac biolabs Research Revised May 30, 2026 2 min read

Our opinion on this compound

70/100

TPP-conjugated ubiquinone with real human trials. The mitochondrial targeting is genuinely different from CoQ10

MitoQ is one of the more rigorous compounds in the mitochondrial-targeting space. The Murphy and Smith work going back to the 1990s built a chemistry strategy for getting molecules concentrated in mitochondria by conjugating them to triphenylphosphonium (TPP+), a lipophilic cation that accumulates in the negatively charged mitochondrial matrix at concentrations roughly 1000-fold higher than cytosol. MitoQ specifically is ubiquinone conjugated to TPP through a ten-carbon linker, designed to deliver redox-cycling antioxidant function directly to the mitochondrial inner membrane.

The human trial story is one of the better-developed in the mitochondrial space. The Rossman 2018 work on endothelial function in older adults at 20mg/day showed measurable improvements in flow-mediated dilation, the Snow 2010 Parkinson's trial was less positive on disease-modification endpoints but informed safety, and the Gioscia-Ryan 2014 work on aortic stiffness in aged mice translated to follow-on human aortic stiffness work showing modest improvements. The signals are not enormous but the consistency on vascular aging endpoints in older adults is unusual for an antioxidant compound, where the negative trial history is long.

Mechanism is plausibly distinct from generic antioxidants. The mitochondrial accumulation means redox chemistry happens where mitochondrial ROS is generated, not in plasma where most dietary antioxidants get neutralized. The TPP+ moiety also has its own pharmacology (membrane potential disruption at high concentrations can be a feature or a bug depending on the application).

What we like: rigorous chemistry, identified target compartment, modest but replicated human signals on vascular aging endpoints, and a development team with serious mitochondrial biology pedigree. The whole TPP-conjugation approach (MitoQ is one of several TPP-targeted compounds in development) is a legitimately interesting drug-development strategy.

What we dont like is the supplement-market positioning. MitoQ is sold as a general anti-aging antioxidant when the human evidence is mostly on specific vascular endpoints in older adults. The cost is also significant given the manufacturing complexity, and generics or copycats are highly variable in actual TPP-conjugated content.

Sourcing: original MitoQ Limited material has been the most-studied. Generic TPP-ubiquinone (mitoquinol or related) is available from specialty research-chemical suppliers but quality and exact compound identity varies. HPLC verification is essential.

One of the more legitimately differentiated mitochondrial compounds out there. Modest effects, real biology, expensive.

Evidence: 68
Mechanism: 80
Reliability: 68
Safety: 80
Sourcing: 70
Value: 50
Signal: 72
Staying power: 72

Plain-language summary Intrigue 75 / 100

MitoQ is mitochondria-targeted ubiquinone (a derivative of CoQ10 with a positively charged triphenylphosphonium group that drives accumulation in mitochondria). Concentrates antioxidant activity at the mitochondrial inner membrane where oxidative damage occurs. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Mitochondria-targeted ubiquinone

A mitochondria-targeted ubiquinone analog with triphenylphosphonium cation for selective mitochondrial accumulation, with cardiovascular endothelial function clinical evidence.

Abstract

MitoQ (mitoquinone mesylate; CAS 845959-50-4; molecular formula C37H44O4P+ mesylate; molecular weight 678.83) is a mitochondria-targeted antioxidant developed by Mike Murphy and Robin Smith at MRC Mitochondrial Biology Unit (Cambridge). The compound consists of ubiquinone (the antioxidant moiety of CoQ10) coupled to a triphenylphosphonium (TPP+) cation through a 10-carbon alkyl chain. The TPP+ cation is membrane-permeant and accumulates 100- to 1000-fold in mitochondria due to the membrane potential, delivering the antioxidant selectively to the site of greatest reactive oxygen species generation. The compound has been studied in cardiovascular endothelial function, neurodegenerative disease, and aging applications. Phase 2 trials in age-related vascular dysfunction showed improvements in flow-mediated dilation. The compound is sold as a dietary supplement (MitoQ Limited). Reported research dose ranges in the literature span 5 to 20 mg.

Mechanism of action

Mitochondria-targeted ubiquinone via TPP+ cation. 100-1000x mitochondrial accumulation through membrane potential.

Reported research dose ranges

Reported research dose ranges in the literature: 5 to 20 mg.

References

Rossman MJ, et al. Chronic supplementation with a mitochondrial antioxidant (MitoQ) improves vascular function in healthy older adults. Hypertension 2018.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, reported research dose ranges, sourcing and quality verification, reconstitution and handling, stack interaction considerations, and a curated reference list. Available as a research-use-only PDF download.

KDC-MN-118

The full reference document is provided strictly for research use only. It reports research dose ranges from the published literature, not instructions for use in humans or animals.

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

Kodiac sells research compounds for investigative use only.

MitoQ

Abstract

Mechanism of action

Reported research dose ranges

References

Read the full monograph

Quick actions

Categories

Help and policies

Abstract

Mechanism of action

Reported research dose ranges

References

Read the full monograph

Adjacent monographs